B. Markman

900 citations

20 papers · 688 indexed · h-index 8

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Oncology 11
- Cancer Immunotherapy and Biomarkers 7
- Pancreatic and Hepatic Oncology Research 2
- CAR-T cell therapy research 2
Physiology 1

Co-authors: José Baselga (3 shared papers)Marta Guzmán (2 shared papers)Violeta Serra (2 shared papers)Ludmila Prudkin (1 shared paper)Pieter J.A. Eichhorn (1 shared paper)Manuela Gili (1 shared paper)Joaquı́n Arribas (1 shared paper)Sarat Chandarlapaty (1 shared paper)
Journals: Annals of Oncology (8 papers)Journal of Clinical Oncology (4 papers)Cancer Research (2 papers)Molecular Cancer Therapeutics (1 paper)Clinical Trials (1 paper)
Partner nations: Australia United States Spain

In The Last Decade

B. Markman

19 papers receiving 677 citations

Peers

Countries citing papers authored by B. Markman

Since Specialization

Citations

This map shows the geographic impact of B. Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Markman more than expected).

Fields of papers citing papers by B. Markman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Markman. The network helps show where B. Markman may publish in the future.

Co-authors

The 25 scholars most cited alongside B. Markman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B. Markman Line = papers co-authored together B. Markman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene ·Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin, Pieter J.A. Eichhorn, Yasir H. Ibrahim, Sarat Chandarlapaty, B. Markman, Olga Rodríguez, Marta Guzmán, Sarai Rodríguez, Manuela Gili, Michelangelo Russillo, Josep-Lluís Parra, Sharat Singh, Joaquı́n Arribas, Neal Rosen, José Baselga	2011	433
2	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors Annals of Oncology ·B. Markman, Josep Tabernero, Ian E. Krop, Geoffrey I. Shapiro, Lillian L. Siu, L.C. Chen, Monica Mita, M. Melendez Cuero, Simone Stutvoet, Diana C. Birle, Oezlem Anak, Wolfgang Hackl, José Baselga	2012	115
3	A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors Journal of Clinical Oncology ·Patricia LoRusso, B. Markman, Josep Tabernero, Ronald Shazer, Linh T. Nguyen, Elisabeth I. Heath, Amita Patnaik, K. Papadopoulos	2009	32
4	Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors Cancer Research ·Leisha A. Emens, John D. Powderly, Lawrence Fong, Joshua Brody, Patrick M. Forde, Matthew D. Hellmann, Brett Hughes, Shivaani Kummar, Sherene Loi, Jason J. Luke, Daruka Mahadevan, B. Markman, Ian McCaffery, Richard A. Miller, Ginna G. Laport	2017	27
5	A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, B. Markman, Josep Tabernero, Akash Patnaik, Elisabeth I. Heath, Arthur P. DeCillis, Douglas Laird, Sunil Aggarwal, L.N. Nguyen, Patricia LoRusso	2008	20
6	Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors Molecular Cancer Therapeutics ·Jeffrey Clarke, Siu-Chung Chu, Lillian L. Siu, Jean‐Pascal Machiels, B. Markman, Kimberley M. Heinhuis, Michael Millward, Martijn P. Lolkema, Sandip Pravin Patel, Paul de Souza, Giuseppe Curigliano, Armando Santoro, Michelle Brown, Ronald A. Fleming, Heather Vezina, Chunsheng He, Sylvie Rottey	2019	16
7	Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC) Annals of Oncology ·Chia-Jui Yen, B. Markman, Yee Chao, Andrew Hill, Jinyu Kang, Lai Wang, Kang Li, Qinzhou Qi, Zhong Wu, Hui Gan	2017	11
8	216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors European Journal of Cancer Supplements ·B. Markman, P. LoRusso, Akash Patnaik, Elisabeth I. Heath, Alexander Laird, Barbara L. van Leeuwen, K. Papadopoulos, José Baselga	2008	10
9	Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC). Journal of Clinical Oncology ·B. Markman, Carlos Gomez‐Roca, Andrés Cervantes, Jean‐Pierre Delord, Luis Paz Ares, Jean‐Charles Soria, J. Corral, Simon J. Hollingsworth, Lucio Manenti, Josep Tabernero	2010	6
10	OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R) Journal of Thoracic Oncology ·Solange Peters, Daniel C. Christoph, John K. Field, R. Fietkau, Andrea Riccardo Filippi, Marina Chiara Garassino, Pilar Garrido, F. McDonald, F. Mornex, B. Markman, Benjamin Solomon, S. Anand, P. Chander, Y. Qiao, N. Girard	2023	3
11	Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb) Annals of Oncology ·Lisa G. Horvath, Jayesh Desai, Shahneen Sandhu, Anne O’Donnell, Andrew Hill, Sanjeev Deva, B. Markman, Michael B. Jameson, Z. Chen, Xuemei Tan, Jeannie Hou, Annette M. Lim	2017	3
12	1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy Annals of Oncology ·Nicolas Girard, Rainer Fietkau, Marina Chiara Garassino, Pilar Garrido, John K. Field, Solange Peters, Hans J.M. Smit, M. Pérol, P. Merle, Anne Sibille, B. Markman, Hasna Bouchaab, Mor Moskovitz, Christian Schumann, Vanesa Gregorc, Alyssa Klein, I. Diaz Perez, W. Sawyer, Muriel Licour, Daniel C. Christoph	2020	2
13	Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study Cancer Research ·Jayesh Desai, B. Markman, Michael Friedländer, Hui Gan, Lisa G. Horvath, Amanda Townsend, Michael Millward, Michael B. Jameson, Chia‐Jui Yen, Ming‐Mo Hou, Jeannie Hou, John Wu, Liang Liang, Sanjeev Deva	2019	2
14	1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) Annals of Oncology ·Quincy S. Chu, Kaushal Parikh, Luis Paz‐Ares, Alejandro Navarro, B. Markman, R. Sarmiento, Georgia Kollia, Chao He, Kinjal Sanghavi, Chang Han, Bruce S. Fischer, Udayan Guha, Sarah Tannenbaum-Dvir, Kunpeng Wu, Y. Liu, Neal Ready	2021	2
15	Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors Annals of Oncology ·Jayesh Desai, Mark Voskoboynik, B. Markman, Jiahui Hou, Dadi Zeng, Tarek Meniawy	2018	2
16	535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma Annals of Oncology ·Juan Martín Liberal, Peter C.C. Fong, Víctor Moreno, Sophia Frentzas, Jayesh Desai, Tarek Meniawy, B. Markman, Mark Voskoboynik, Nageshwar Budha, Junwei Wu, Wei Shen, Meenakshi Singh, Emiliano Calvo	2020	1
17	Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type (WT) and activating PI3K mutations Journal of Clinical Oncology ·B. Markman, Violeta Serra, M. Scaltriti, V. Valero, Marta Guzmán, C. Garcia-Echevarria, Michel Maira, J. Baselga	2008	1
18	Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study Clinical Trials ·Jayesh Desai, B. Markman, Michael Friedländer, Hui Gan, Lisa G. Horvath, Amanda Townsend, Michael Millward, Michael B. Jameson, Chia‐Jui Yen, Ming‐Mo Hou, Jeannie Hou, Chih-Hang John Wu, Liang Liang, Sanjeev Deva	2019	1
19	Membrane receptors as targets for therapeutic approaches in colorectal cancer Teresa Macarulla, B. Markman, Josep Tabernero	2010	1
20	916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors Annals of Oncology ·J. Desai, B. Markman, M. Millward, E. Garralda, Z.A.A. Wainberg, Martin Gutierrez, James A. Henry, H. Park, Rasha Cosman, Antoine Hollebecque, M.J. Borad, Ali McBride, Linda Favre-Kontula, Ming Zhou, Aidan G. Gilmartin, X. Gong, M. Hidalgo	2025	0

About B. Markman

B. Markman is a scholar working on Oncology, Physiology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Reproductive Medicine, having authored 20 papers that have together received 688 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Lung Cancer Treatments and Mutations (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Pancreatic and Hepatic Oncology Research (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), Bladder and Urothelial Cancer Treatments (2 papers) and CAR-T cell therapy research (2 papers). The work is most often cited by research in Oncology (293 citations), Genetics (102 citations), Molecular Biology (469 citations), Pathology and Forensic Medicine (88 citations) and Pulmonary and Respiratory Medicine (152 citations). B. Markman has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include José Baselga, Marta Guzmán, Violeta Serra, Ludmila Prudkin, Pieter J.A. Eichhorn, Manuela Gili, Joaquı́n Arribas, Sarat Chandarlapaty, Josep-Lluís Parra and Michelangelo Russillo. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Research, Molecular Cancer Therapeutics and Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact